English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Combined bezafibrate and medroxyprogesterone acetate : potential novel therapy for acute myeloid leukaemia

Khanim, F. L., Hayden, R. E., Birtwistle, J., Lodi, A., Tiziani, S., Davies, N. J., et al. (2009). Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS ONE, 4(12), e8147-e8147. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785482/pdf/pone.0008147.pdf.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0010-7CAC-E Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0010-7CAE-A
Genre: Journal Article

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Khanim, Farhat L., Author
Hayden, Rachel E., Author
Birtwistle, Jane, Author
Lodi, Alessia, Author
Tiziani, Stefano, Author
Davies, Nicholas J., Author
Ride, Jon P., Author
Viant, Mark R., Author
Gunther, Ulrich L., Author
Mountford, Joanne C., Author
Schrewe, Heinrich1, Author              
Green, Richard M., Author
Murray, Jim A., Author
Drayson, Mark T., Author
Chris, M. Bunce, Author
Affiliations:
1Dept. of Developmental Genetics (Head: Bernhard G. Herrmann), Max Planck Institute for Molecular Genetics, Max Planck Society, ou_1433548              

Content

show
hide
Free keywords: -
 Abstract: Background The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have anti-leukaemic activity but that, unlike conventional chemotherapy, do not impair normal haemopoiesis. Principal Findings Here we demonstrate the potent anti-leukaemic activity of the combination of the lipid-regulating drug bezafibrate (BEZ) and the sex hormone medroxyprogesterone acetate (MPA) against AML cell lines and primary AML cells. The combined activity of BEZ and MPA (B/M) converged upon the increased synthesis and reduced metabolism of prostaglandin D2 (PGD2) resulting in elevated levels of the downstream highly bioactive, anti-neoplastic prostaglandin 15-deoxy Δ12,14 PGJ2 (15d-PGJ2). BEZ increased PGD2 synthesis via the generation of reactive oxygen species (ROS) and activation of the lipid peroxidation pathway. MPA directed prostaglandin synthesis towards 15d-PGJ2 by inhibiting the PGD2 11β -ketoreductase activity of the aldo-keto reductase AKR1C3, which metabolises PGD2 to 9α11β-PGF2α. B/M treatment resulted in growth arrest, apoptosis and cell differentiation in both AML cell lines and primary AML cells and these actions were recapitulated by treatment with 15d-PGJ2. Importantly, the actions of B/M had little effect on the survival of normal adult myeloid progenitors. Significance Collectively our data demonstrate that B/M treatment of AML cells elevated ROS and delivered the anti-neoplastic actions of 15d-PGJ2. These observations provide the mechanistic rationale for the redeployment of B/M in elderly and relapsed AML.

Details

show
hide
Language(s): eng - English
 Dates: 2009-12-07
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: PLoS ONE
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 4 (12) Sequence Number: - Start / End Page: e8147 - e8147 Identifier: -